MedTrace Logo

Phase II Study of Carmustine, Streptozocin, and Mercaptopurine for Refractory or Recurrent Brain Neoplasms

NCT00004688 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2015-03-25

No results posted yet for this study

Summary

OBJECTIVES:

I. Assess the clinical response of patients with refractory or recurrent brain neoplasms treated with carmustine, streptozocin, and mercaptopurine.

Conditions

Interventions

DRUG

carmustine

DRUG

mercaptopurine

DRUG

streptozocin

Sponsors & Collaborators

  • Emory University

    lead OTHER

Principal Investigators

  • Mark R. Gilbert · Emory University

Study Design

Purpose
TREATMENT

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
1996-08-31
Completion
1998-07-31

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00004688 on ClinicalTrials.gov